Stockscreener 앱 받기
1.65
3.77%
0.06
전일 마감가:
$1.59
열려 있는:
$1.59
하루 거래량:
59,182
Relative Volume:
0.03
시가총액:
$8.24M
수익:
-
순이익/손실:
$-11.46M
주가수익비율:
-0.1179
EPS:
-14
순현금흐름:
$-24.56M
1주 성능:
+26.05%
1개월 성능:
-5.71%
6개월 성능:
-88.04%
1년 성능:
-91.99%
1일 변동 폭
$1.59
$1.70
1주일 범위
$1.25
$1.70
52주 변동 폭
$1.20
$21.65
에바종 바이오테크 Stock (EVAX) Company Profile
EVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVAX
Evaxion Biotech A S Adr
|
1.65 | 8.24M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
에바종 바이오테크 Stock (EVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-02 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-02-12 | 개시 | H.C. Wainwright | Buy |
에바종 바이오테크 주식(EVAX)의 최신 뉴스
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
Evaxion Biotech’s Optimistic Earnings Call Highlights - TipRanks
Evaxion Biotech Reports 2024 Financial Results and Strategic Progress - TipRanks
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
Evaxion Biotech stock plunges to 52-week low of $1.7 amid steep annual decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - TradingView
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $1.79 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
EVAX: Extended Trial is Excellent News - Research Tree
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
After A Decline Of -818.6% From The High, Can Evaxion Biotech A/S ADR (NASDAQ: EVAX) Recover Quickly? - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
Top investors say Evaxion Biotech A/S ADR (EVAX) ticks everything they need - SETE News
Evaxion Biotech A/S ADR [EVAX] Investment Guide: What You Need to Know - Knox Daily
Now Is The Time To Build A Position In Evaxion Biotech A/S ADR (NASDAQ:EVAX) - Marketing Sentinel
Evaxion Biotech A/S ADR (EVAX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Palantir Technologies Surges 16.5% in Pre-Market Trading After Strong Q4 Earnings Report - HPBL
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Argo Blockchain Plc ADR (ARBK)’s stock price in review: A technical analysis - US Post News
Evaxion Biotech A/S ADR (EVAX)’s stock decline to 2.40 per share - US Post News
Daily Market Movement: Onconetix Inc (ONCO) Sees a 11.91 Increase, Closing at 0.61 - The Dwinnex
In the Green: Evaxion Biotech A/S ADR (EVAX) Closes at 2.40, Up/Down -2.24 from Previous Day - The Dwinnex
Market Insights: Kairos Pharma Ltd (KAPA)’s Notable Gain of 6.29, Closing at 1.52 - The Dwinnex
Palantir Technologies at a Crossroads: Sky-High Valuation or Looming Market Correction? - HPBL
Hodges Capital Management Takes $16.5 Million Stake in Palantir Technologies (PLTR) – market - HPBL
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
Major Pharma Giant's VC Fund Doubles Down on Evaxion Biotech in $10.8M Strategic Round - StockTitan
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Monday Trading - MSN
When Will Evaxion Biotech A/S ADR. (EVAX) Be Worth Investing In? - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
Investing Now Could Prove Beneficial For Evaxion Biotech A/S ADR (NASDAQ: EVAX) - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
Future Outlook And Stock Price Performance For Evaxion Biotech A/S ADR (NASDAQ: EVAX) - Marketing Sentinel
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline By Investing.com - Investing.com South Africa
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Evaxion Biotech Completes 1:5 Reverse ADS Split: What Investors Need to Know - Stock Titan
에바종 바이오테크 (EVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):